<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Made in Russia antilymphocytic globulin (ALG) was given to 43 patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) </plain></SENT>
<SENT sid="1" pm="."><plain>56% of the patients responded, 30% reached a complete or partial remission </plain></SENT>
<SENT sid="2" pm="."><plain>5-year actuarial survival of ALG-treated patients was 52% (44 and 60% for severe and non-severe forms) </plain></SENT>
<SENT sid="3" pm="."><plain>The data on ALG efficacy suggest its benefits in first-line therapy of both severe and non-severe AA as well as in management of patients resistant to other methods of immunosuppressive treatment </plain></SENT>
</text></document>